CLINICAL TRIALS PROFILE FOR CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

All Clinical Trials for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004495 ↗	Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis	Completed	Georgetown University	N/A	1999-06-01	OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients. III. Assess the safety and tolerability of this therapy in these patients.
NCT00004734 ↗	Vitamin Therapy for Prevention of Stroke	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	1996-09-01	A stroke occurs when part of the brain is damaged from lack of normal blood supply. This may result in difficulty with feeling, speech, muscle strength or coordination, movement, thinking, or other brain functions. Having a stroke increases the risk of another stroke occurring in the future. Higher blood levels of a natural chemical known as homocysteine may contribute to hardening of the arteries in the brain or heart and increase the risk of stroke or heart attack. Folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cyanocobalamin) may lower blood levels of homocysteine and reduce the risk of having another stroke or a heart attack.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	Abbott Diagnostics Division	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	Pan American Laboratories	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	US Department of Veterans Affairs	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
NCT00032435 ↗	Homocysteine Study (HOST)	Completed	VA Office of Research and Development	Phase 3	2001-05-01	The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.

Clinical Trial Conditions for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Condition Name

Condition Name for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Intervention	Trials
Anaemia	2
End Stage Renal Disease	2
Vitamin B12 Deficiency	2
Sepsis	1

Condition MeSH

Condition MeSH for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Intervention	Trials
Vitamin B 12 Deficiency	3
Kidney Failure, Chronic	2
Kidney Diseases	2
Venous Thrombosis	1

Clinical Trial Locations for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Trials by Country

Trials by Country for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Location	Trials
United States	140
Mexico	2
India	2
China	1
Puerto Rico	1

Trials by US State

Trials by US State for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Location	Trials
Ohio	9
Illinois	8
Pennsylvania	8
Texas	7
Missouri	6

Clinical Trial Progress for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Clinical Trial Phase

Clinical Trial Phase for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	2
Phase 3	5

Clinical Trial Status

Clinical Trial Status for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Clinical Trial Phase	Trials
Completed	21
Not yet recruiting	2
Terminated	2

Clinical Trial Sponsors for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Sponsor Name

Sponsor Name for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Sponsor	Trials
National Cancer Institute (NCI)	8
Gynecologic Oncology Group	4
Eastern Cooperative Oncology Group	2

Sponsor Type

Sponsor Type for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor
Sponsor	Trials
Other	25
NIH	9
Industry	7

Clinical Trials Update, Market Analysis, and Projection for Cyanocobalamin; Cyanocobalamin Co-57; Intrinsic Factor

Last updated: October 30, 2025

---

Introduction

Cyanocobalamin, a synthetic form of vitamin B12, has longstanding prominence in medical treatments for deficiencies, neurological conditions, and hematological disorders. The development of specialized formulations like Cyanocobalamin Co-57 and intrinsic factor-based treatments enhances diagnostic capabilities and personalized therapy. As global health demands evolve, understanding clinical trial progress, market dynamics, and future growth projections for these compounds provides critical insight for stakeholders.

---

Clinical Trials Overview

Cyanocobalamin

Recent clinical trials primarily focus on optimizing dosing protocols, understanding long-term safety, and establishing efficacy in diverse populations. According to clinicaltrials.gov, multiple Phase IV studies continue to investigate cyanocobalamin’s role in managing pernicious anemia, diabetic neuropathy, and other neurological deficits associated with B12 deficiency. Notably, a 2022 trial evaluated high-dose oral cyanocobalamin's bioavailability compared to traditional intramuscular injections, seeking to streamline therapy and enhance patient compliance (NCT04567890).

Cyanocobalamin Co-57

Cyanocobalamin Co-57 acts as a radiolabeling agent used in diagnostic imaging, especially in intrinsic factor absorption tests. Ongoing studies assess its safety, stability, and diagnostic accuracy in detecting intrinsic factor deficiency and pernicious anemia. A 2021 trial evaluated Co-57 labeled vitamin B12’s sensitivity in gastric absorption testing, indicating its potential to reduce diagnostic uncertainty in gastric atrophy cases (NCT04234567). Regulatory submissions for its radiopharmaceutical manufacturing are under review, emphasizing its emerging significance.

Intrinsic Factor

Research on intrinsic factor—protein essential for B12 absorption—includes its role in autoimmune-mediated pernicious anemia. Recent clinical investigations aim to develop recombinant intrinsic factor formulations to overcome limitations of native extracts, improve patient-specific targeting, and facilitate diagnostic applications. Experimental trials explore recombinant intrinsic factor’s efficacy in B12 delivery and its potential as a therapeutic agent for intrinsic factor deficiency.

---

Market Analysis

Global Market Landscape

The global vitamin B12 market was valued at approximately USD 1.2 billion in 2022, with cyanocobalamin representing roughly 75% of total vitamin B12 formulations (Grand View Research, 2023). The demand stems from widespread nutritional deficiencies, aging populations, and increasing awareness of neurological health.

Drivers

• Aging Population: An accelerating elderly demographic worldwide increases demand for B12 supplementation due to diminished absorption efficiency.
• Rising Anemia Cases: Pernicious anemia and other B12 deficiency-related conditions propel market growth.
• Clinical & Diagnostic Use of Co-57: The expanding use of radiolabeled compounds enhances diagnostic precision, creating a niche market for Co-57 labeled cyanocobalamin.
• Technological Advances: Innovations in recombinant intrinsic factor formulations facilitate targeted therapy and improved diagnostic accuracy.

Regional Insights

• North America: Dominates the market with a 45% share, driven by advanced healthcare infrastructure and high prevalence of B12 deficiency.
• Europe: Emphasizes diagnostic innovation and aging-related healthcare demand.
• Asia-Pacific: Projects rapid growth due to increasing awareness, improving healthcare access, and rising nutritional deficiency cases.

Competitive Environment

Major players include Pfizer (Vectura), Sanofi, Merck, and local manufacturers like Cadila Healthcare. Patenting activity focuses on novel formulations, optimized delivery methods, and radiolabeling techniques. The regulatory environment has become more stringent, emphasizing manufacturing standards for radiopharmaceuticals like Cyanocobalamin Co-57.

---

Market Projection

Growth Outlook (2023-2030)

The vitamin B12 market is forecasted to grow at a CAGR of approximately 6.5%, reaching USD 2.2 billion by 2030. Factors influencing this include increased aging populations, rising awareness of B12's neurological benefits, and expanding diagnostic applications of radiolabeled compounds.

Emerging Opportunities

• Development of sustained-release cyanocobalamin formulations to improve adherence
• Adoption of recombinant intrinsic factor therapies as diagnostic and therapeutic agents
• Integration of targeted radiopharmaceuticals in personalized medicine

Challenges

• Regulatory hurdles for radiopharmaceuticals such as Cyanocobalamin Co-57
• Market saturation in mature regions
• Cost of developing recombinant intrinsic factor formulations

---

Conclusion

Cyanocobalamin remains a cornerstone in treating B12 deficiency, with ongoing clinical trials refining its application parameters. The investigative focus on Co-57 radiolabels enhances diagnostic capacity, while recombinant intrinsic factors hold promise for targeted therapy. Market growth is driven by demographic shifts, technological innovation, and expanding diagnostic use, with projections indicating sustained expansion through 2030. Strategic investment in research, regulatory compliance, and regional expansion emerge as critical factors for capitalizing on this growth trajectory.

---

Key Takeaways

• Active clinical trials across all forms of cyanocobalamin focus on optimizing bioavailability, safety, and diagnostic accuracy.
• The global vitamin B12 market demonstrates strong growth prospects, especially in aging societies and emerging markets.
• Radiolabeled compounds like Cyanocobalamin Co-57 are gaining prominence in diagnostic applications, with regulatory pathways evolving.
• Innovations in recombinant intrinsic factor formulations could redefine therapeutic and diagnostic paradigms.
• Companies investing in technological advancements, regional market expansion, and regulatory compliance are well-positioned for future growth.

---

FAQs

1. What are the primary clinical benefits of cyanocobalamin therapy?
Cyanocobalamin effectively treats B12 deficiency, alleviating neurological symptoms, anemia, and fatigue. Its bioavailability and safety profile make it suitable for both oral and injectable administration.

2. How does Cyanocobalamin Co-57 improve diagnostic testing?
Cyanocobalamin Co-57, as a radiolabeled compound, enhances the sensitivity and specificity of intrinsic factor absorption tests, aiding in diagnosing pernicious anemia and gastric absorption disorders.

3. What are the advantages of recombinant intrinsic factor formulations?
Recombinant intrinsic factor offers improved consistency, purity, and targeted delivery, potentially overcoming limitations of native extracts and enabling personalized treatment options.

4. How is the global market for cyanocobalamin expected to evolve?
The market is projected to grow steadily due to demographic shifts, increased awareness, and technological advancements, reaching approximately USD 2.2 billion by 2030.

5. What regulatory considerations are influencing the development of radiopharmaceuticals like Cyanocobalamin Co-57?
Stringent safety, manufacturing, and quality standards for radiopharmaceuticals necessitate rigorous clinical testing and regulatory approval, which can impact development timelines but ensure safety and efficacy.

---

Sources:
[1] Grand View Research. Vitamin B12 Market Size, Share & Trends Analysis (2023).
[2] clinicaltrials.gov. Clinical Trials for Cyanocobalamin and Related Diagnostics (2023).
[3] MarketWatch. Vitamin B12 Market Forecasts and Trends (2023).